476 related articles for article (PubMed ID: 29122757)
1. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.
Legut M; Dolton G; Mian AA; Ottmann OG; Sewell AK
Blood; 2018 Jan; 131(3):311-322. PubMed ID: 29122757
[TBL] [Abstract][Full Text] [Related]
2. Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function.
Schober K; Müller TR; Gökmen F; Grassmann S; Effenberger M; Poltorak M; Stemberger C; Schumann K; Roth TL; Marson A; Busch DH
Nat Biomed Eng; 2019 Dec; 3(12):974-984. PubMed ID: 31182835
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells.
Kamali E; Rahbarizadeh F; Hojati Z; Frödin M
BMC Biotechnol; 2021 Jan; 21(1):9. PubMed ID: 33514392
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study.
Safarzadeh Kozani P; Shokrgozar MA; Evazalipour M; Roudkenar MH
Int Immunopharmacol; 2022 Sep; 110():109055. PubMed ID: 35853277
[TBL] [Abstract][Full Text] [Related]
5. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells.
Seki A; Rutz S
J Exp Med; 2018 Mar; 215(3):985-997. PubMed ID: 29436394
[TBL] [Abstract][Full Text] [Related]
6. Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.
Lo Presti V; Meringa A; Dunnebach E; van Velzen A; Moreira AV; Stam RW; Kotecha RS; Krippner-Heidenreich A; Heidenreich OT; Plantinga M; Cornel A; Sebestyen Z; Kuball J; van Til NP; Nierkens S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580329
[TBL] [Abstract][Full Text] [Related]
7. Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.
Hiasa A; Nishikawa H; Hirayama M; Kitano S; Okamoto S; Chono H; Yu SS; Mineno J; Tanaka Y; Minato N; Kato I; Shiku H
Gene Ther; 2009 May; 16(5):620-8. PubMed ID: 19242528
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic.
Morton LT; Reijmers RM; Wouters AK; Kweekel C; Remst DFG; Pothast CR; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2020 Jan; 28(1):64-74. PubMed ID: 31636040
[TBL] [Abstract][Full Text] [Related]
9. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.
van der Veken LT; Hagedoorn RS; van Loenen MM; Willemze R; Falkenburg JH; Heemskerk MH
Cancer Res; 2006 Mar; 66(6):3331-7. PubMed ID: 16540688
[TBL] [Abstract][Full Text] [Related]
10. Orthotopic T-cell receptor replacement in primary human T cells using CRISPR-Cas9-mediated homology-directed repair.
Moosmann C; Müller TR; Busch DH; Schober K
STAR Protoc; 2022 Mar; 3(1):101031. PubMed ID: 34977677
[TBL] [Abstract][Full Text] [Related]
11. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
12. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
13. Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo.
van der Veken LT; Coccoris M; Swart E; Falkenburg JH; Schumacher TN; Heemskerk MH
J Immunol; 2009 Jan; 182(1):164-70. PubMed ID: 19109147
[TBL] [Abstract][Full Text] [Related]
14. Non-viral precision T cell receptor replacement for personalized cell therapy.
Foy SP; Jacoby K; Bota DA; Hunter T; Pan Z; Stawiski E; Ma Y; Lu W; Peng S; Wang CL; Yuen B; Dalmas O; Heeringa K; Sennino B; Conroy A; Bethune MT; Mende I; White W; Kukreja M; Gunturu S; Humphrey E; Hussaini A; An D; Litterman AJ; Quach BB; Ng AHC; Lu Y; Smith C; Campbell KM; Anaya D; Skrdlant L; Huang EY; Mendoza V; Mathur J; Dengler L; Purandare B; Moot R; Yi MC; Funke R; Sibley A; Stallings-Schmitt T; Oh DY; Chmielowski B; Abedi M; Yuan Y; Sosman JA; Lee SM; Schoenfeld AJ; Baltimore D; Heath JR; Franzusoff A; Ribas A; Rao AV; Mandl SJ
Nature; 2023 Mar; 615(7953):687-696. PubMed ID: 36356599
[TBL] [Abstract][Full Text] [Related]
15. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
16. γδTCR immunoglobulin constant region domain exchange in human αβTCRs improves TCR pairing without altering TCR gene-modified T cell function.
Tao C; Shao H; Zhang W; Bo H; Wu F; Shen H; Huang S
Mol Med Rep; 2017 Apr; 15(4):1555-1564. PubMed ID: 28259946
[TBL] [Abstract][Full Text] [Related]
17.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
18. Evidence that gammadelta versus alphabeta T cell fate determination is initiated independently of T cell receptor signaling.
Kang J; Volkmann A; Raulet DH
J Exp Med; 2001 Mar; 193(6):689-98. PubMed ID: 11257136
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-engineered T cells in patients with refractory cancer.
Stadtmauer EA; Fraietta JA; Davis MM; Cohen AD; Weber KL; Lancaster E; Mangan PA; Kulikovskaya I; Gupta M; Chen F; Tian L; Gonzalez VE; Xu J; Jung IY; Melenhorst JJ; Plesa G; Shea J; Matlawski T; Cervini A; Gaymon AL; Desjardins S; Lamontagne A; Salas-Mckee J; Fesnak A; Siegel DL; Levine BL; Jadlowsky JK; Young RM; Chew A; Hwang WT; Hexner EO; Carreno BM; Nobles CL; Bushman FD; Parker KR; Qi Y; Satpathy AT; Chang HY; Zhao Y; Lacey SF; June CH
Science; 2020 Feb; 367(6481):. PubMed ID: 32029687
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
Ghaffari S; Khalili N; Rezaei N
J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
